R&D strategy

Our research & development strategy is guided by the principle of service to patients, to deliver therapeutic solutions for unmet medical needs, in oncology, neurosciences and rare diseases. We are recognized for our unique expertise in neurotoxin biology.

Bloc image R&D
Pipeline

Pipeline

Ipsen R&D has a valuable pipeline encompassing both lifecycle management of our well-established products, and the development of innovative new molecules, including small molecules, neurotoxins and theranostics.

Three therapeutic areas

Ipsen focuses on three therapeutic areas, oncology, neurosciences and rare diseases, developing innovative and differentiated therapies in areas of high unmet medical need. Our specialized portfolio of products, combined with our strong clinical and regulatory skillset, will allow us to continue to expand indications across existing therapies and bring new treatments for patients.

KFP_2846
Cambridge_Exterieur

Internationally renowned R&D centers

With an open innovation model in mind, we have placed our three R&D centres at the heart of three internationally reputed scientific hubs: Paris-Saclay in France, Oxford in the United Kingdom and Cambridge in the United States, in contact with leading academic research centers, medical centers and technology companies.

A Development Powerhouse

Our biotech mindset, combined with the scale and advantages of a global pharmaceutical company, has established us as a development powerhouse in our core focus areas. We have therapeutically-aligned teams, global expertise in regulatory affairs, patient safety and medical affairs, and a proven ability to bring new, life changing therapies successfully through clinical development.

View of clinical trials
A3_CHRO_M3A5788

 External Innovation

We make sure we access the best information and opportunities provided through external networks, and maximize the potential for in-licensing novel and life-changing treatments. The partnerships that we develop with leading academic institutes, biotechs and medical centers allow us to test the relevance of our research concepts.

Last update 06/03/2017